ViewRay Inc. (VRAY) Releases Earnings Results, Misses Expectations By $0.08 EPS
Shares of ViewRay (NASDAQ:VRAY) opened at 2.79 on Tuesday. ViewRay has a 12-month low of $2.64 and a 12-month high of $8.00. The firm’s market capitalization is $107.12 million. The company has a 50-day moving average price of $3.63 and a 200 day moving average price of $3.98.
In related news, Director Aditya Puri purchased 1,472,803 shares of the company’s stock in a transaction on Friday, September 9th. The shares were bought at an average cost of $2.95 per share, for a total transaction of $4,344,768.85. Following the transaction, the director now owns 18,964 shares of the company’s stock, valued at $55,943.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David P. Bonita purchased 1,138,074 shares of the company’s stock in a transaction on Monday, August 22nd. The shares were bought at an average price of $2.95 per share, for a total transaction of $3,357,318.30. The disclosure for this purchase can be found here. Company insiders own 59.10% of the company’s stock.
Separately, BTIG Research began coverage on ViewRay in a research report on Wednesday, September 14th. They set a “buy” rating and a $6.00 target price on the stock.
ViewRay Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Stock Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related stocks with our FREE daily email newsletter.